-
Good Health For India: 300+ Products Through 300,000+ Doctors
-
Keeping Our Promises: Affordability, Accessibility, Quality
-
Responsible Pharma: 20 years of ESG
Dr. Reddy’s in India
Every day, our team of over 9,000 employees come to work with a single purpose in mind, ‘Good Health Can’t Wait’.
It is this purpose that has led Dr. Reddy’s India to drive more than 300 products that cover a spectrum of therapy areas – gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Among the top 10 pharma companies in India, you can find a Dr. Reddy’s product in over 70 countries. Our focus on discovery and patient-focused innovation has led to an extensive portfolio that includes APIs, generics, branded generics, biosimilars and OTC. Our people connect with more than 300,000+ doctors across 28 states and UTs to ensure that affordable and quality medicines are within reach of all that need it.
Latest from India
The India business
Our journey began in 1986 and over these thirty years, we’ve established trust in the Indian healthcare sector, securing a position among the top 10 pharmaceutical companies in the Indian Pharma Market (IQVIA MAT, November 2022). Our dedication to healthcare helped us climb from rank 16 to rank 10 in just four years. Read more
15
Journey to success through Young Leadership Program
8,200
Benefitted through our employee health and wellness initiative My Health Index
2,850+
Certified as Digital Ninjas in FY2023
Life at Dr. Reddy’s
Each one of us at Dr.Reddy’s is on a mission passed down to us by our founder Dr.Anji Reddy - medicines for all. With that in mind, we continue to make our work culture and environment such that every single team member is poised for success in this mission, as well as in their personal lives.
A Healthier Tomorrow
In addition to our current growth drivers, we’re shaping the future of healthcare in the country. This includes expanding in nutraceuticals, cell and gene therapy, and New Chemical Entities (NCEs) through our subsidiary Aurigene Oncology Limited.
We’re also venturing into integrated digital healthcare services, digital therapeutics, and disease management. While these ventures are in early stages, we’ve made strides, partnering for trials and commercialisation. We’re innovating with wearable tech for atrial fibrillation and migraine management, advancing CAR-T therapies, and introducing New Biological Entity toripalimab.
As the pharmaceutical landscape evolves, we remain dedicated to foreseeing and investing in future patient needs.